All News

Loaded doesn't kill you

After dealing with a patient who was clearly a marijuana user, a pharmacist reflects on how so much attention is paid to illicit drugs, but very little is given to prescription drug abuse.

Individuals with high cholesterol who stay on their statin medications over a two-year period are healthier than comparable nonadherent individuals, but the overall cost of their care is slightly higher, according to a new study.

The Hennepin County Medical Center (HCMC), based in Minneapolis, Minn., significantly reduced hospital readmissions and emergency room visits by forming an accountable care organization (ACO) team.

New products

A survey of new Rx, new generic, and new OTC products

Letters

Readers discuss taking the time to research, the need for care when purchasing drugs, the need to be more visible to the public, and arguing that cyberconsulting is too dangerous to practice in.

A look at the meningitis outbreak that killed 36 and whether or not legislation could prevent a similar tragedy from occurring.

Two pharmacy students argue that the push needs to continue for attaining provider status and it's important to include students.

The U.S. Preventive Services Task Force (USPSTF) is seeking public comment on its draft recommendation on adult screening for hepatitis C virus (HCV) until Dec. 24, the agency announced.

The Drug Enforcement Administration (DEA) issued a notice to three Walgreens pharmacies in Florida on Nov. 27, asking them to show why the DEA should not revoke their DEA registrations.

More than 40 lots of atorvastatin calcium tablets, the generic version of Pfizer?s Lipitor, are being recalled by Ranbaxy Pharmaceuticals Inc. (RPI) because they may contain glass particles that are estimated to be less than 1 mm in size, according to Ranbaxy's website.

An FDA advisory panel voted against making oxybutynin transdermal patch (Oxytrol, Merck and Watson Pharma) available over-the-counter (OTC) for overactive bladder (OAB) in women, Medpage Today reported.

The Obama administration moved ahead to implement provisions in the healthcare law that would make it illegal for insurance companies to discriminate against people with pre-existing conditions.

Prostaglandin inhibitors and calcium channel blockers were ranked as the top tocolytic therapy options in terms of outcomes of 48-hour delay in delivery, neonatal mortality, respiratory distress syndrome, and maternal side effects, according to a systematic review and network meta-analysis published Oct. 9 in BMJ.